These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Serum adiponectin level in patients of chronic pulmonary heart disease with cardiac failure].
    Author: Shi HF, Ding YP, He HW.
    Journal: Zhonghua Yi Xue Za Zhi; 2008 Sep 23; 88(36):2544-6. PubMed ID: 19080646.
    Abstract:
    OBJECTIVE: To investigate the changes of the concentration of serum adiponectin in patients of chronic pulmonary heart disease (CPHD) with cardiac failure. METHODS: Thirty-eight CPHD patients with cardiac failure underwent conventional treatment, and were divided into 2 subgroups: remission subgroup (n = 32) and non-remission subgroup (n = 6) according to the therapeutic effects 2 weeks later. Peripheral blood samples were collected from these 38 CPHD patients (CPHD group), including the remission subgroup and non-remission subgroup, and 30 healthy persons (as normal control group). Enzyme linked immunosorbent assay (ELISA) was used to detect the serum levels of adiponectin, interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha before and 2 weeks after treatment. RESULTS: The serum adiponectin of the CPHD group was (9.5 +/- 7.1) ng/L in general, significantly lower than that of the normal control group [(21.5 +/- 9.0) ng/L, P < 0.01]. The serum adiponectin of the remission group was (17.0 +/- 6.3) ng/L, significantly higher than that of the non-remission group [(8.1 +/- 4.8) ng/L, P < 0.01], but still significantly lower than that of the normal control group (P < 0.05). The IL-6 and TNF-alpha levels of the CPHD group were (50.0 +/- 17.6) and (53.8 +/- 16.2) ng/L respectively, both significantly higher than those of normal control group [(24.4 +/- 9.1) and (28.4 +/- 11.4) ng/L respectively, both P < 0.01]. The IL-6 and TNF-alpha levels of the remission group were (29.0 +/- 12.1) ng/L and (32.3 +/- 13.5) ng/L respectively, both significantly lower than those of the non-remission group [(56.0 +/- 16.0) and (59.3 +/- 19.1) ng/L respectively, both P < 0.01], but not significantly different from those of the normal control group. There were no significant differences in the adiponectin, IL-6, and TNF-alpha levels between the non-remission group and the CPHD group. CONCLUSIONS: Adiponectin is involved in the pathophysiological process of heart failure in the CPHD patients. It may be a useful index to guide treatment and judge prognosis by dynamically determining the serum adiponectin.
    [Abstract] [Full Text] [Related] [New Search]